Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Am J Transplant. 2021 Mar 17;21(9):3066–3076. doi: 10.1111/ajt.16538

Figure 2. Renal function with q2m belatacept maintenance therapy is non-inferior to standard q1m administration.

Figure 2.

Kidney transplant recipients were randomized to receive q1m or q2m belatacept (5 mg/kg) maintenance therapy and observed over a 12-month study period. (A) Unadjusted mean renal function as measured by eGFR (ml/min/1.73m2) at 12 months post-randomization between groups. Box and whiskers indicate IQR. (B) Unadjusted mean eGFR between groups over the 12-month study period with numbers at risk for each group. Box and whiskers indicate IQR. (C) Observed unadjusted and adjusted difference in mean eGFR between q1m and q2m treatment groups 12 months after randomization. The blue dashed line indicates the pre-specified non-inferiority margin of a mean difference (Δ) in eGFR of 6 ml/min/1.73m2, and the blue tinted region to the left of this line indicates the zone of non-inferiority. The error bars indicate 2-sided 95% CIs for the mean difference in eGFR between groups at 12 months (Table 2). (D) Change in eGFR from baseline (month 0) to end of study (month 12) for each treatment group.